Axsome Therapeutics, Inc. (AXSM) | Investment Case

1. Company Snapshot

1.a. Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.

Axsome Therapeutics, Inc.has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.The company was incorporated in 2012 and is based in New York, New York.

Show Full description

1.b. Last Insights on AXSM

Axsome Therapeutics' recent momentum is driven by the FDA's priority review of AXS-05, its Alzheimer's disease agitation treatment. The company's strong revenue growth, with 65% and 66% annual growth in Q4 and full-year 2025 net product revenue, respectively, also boosted investor confidence. Institutional investors, such as Stanley Laman Group Ltd., have taken notice, with the firm acquiring a new $2.13 million position in the company. Additionally, Axsome's presentation at investor conferences and its expanding product portfolio have contributed to its positive short-term outlook.

1.c. Company Highlights

Last Price	159.5
Change Percentage	-4.11%
Open	164.99
Previous Close	166.34
Market Cap ( Millions)	8159
Volume	615755
Year High	191.5
Year Low	86.99
M A 50	175.61
M A 200	135.15

FCF Yield	-1.15%
Dividend Yield	0.00%
ROE	-254.14%
Debt / Equity	273.28%
Net Debt / EBIDTA	49.04%
Price To Book	91.46
Price Earnings Ratio	-44.09
Price To FCF	-86.97
Price To sales	12.78
EV / EBITDA	-48.52

2. Axsome Therapeutics' Q4 2025 Earnings: Strong Revenue Growth and Pipeline Advancements

Axsome Therapeutics reported a robust fourth quarter and full-year 2025, with total revenue increasing 65% year over year to $196 million and 66% to $639 million for the full year. The company's net loss for the fourth quarter was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share, for 2024. The actual EPS came out at -$0.56406, beating estimates of -$0.7. Auvelity achieved sales of over $500 million in its third full year of launch, with net product sales of $155.1 million for the fourth quarter, up 68% versus the prior year.

Publication Date: Feb -24

                                    📋 Highlights
                                    Revenue Growth:
                                                Q4 revenue rose 65% YoY to $196M, with FY2025 total revenue up 66% to $639M, driven by Auvelity’s $155.1M Q4 sales (68% YoY).<br>
Auvelity’s Market Expansion:
                                                Achieved $500M+ in third-year sales, with 225,000 prescriptions in Q4 (42% YoY growth), and sNDA for Alzheimer’s agitation under priority review (PDUFA April 30).<br>
Sunosi & Cymbravo Performance:
                                                Sunosi sales grew 40% YoY to $36.7M, while Cymbravo generated $4.1M in Q4, with 13,000 prescriptions and 5,300 new patients.<br>
Financial Resilience:
                                                FY2025 net loss narrowed to $74.9M ($1.54/share) from $104.4M ($2.15/share) in 2024, with $323M cash reserves projected to fund operations until cash flow positivity.<br>
Pipeline Advancements:
                                                AXS-05 Phase III for smoking cessation to start Q2 2026, AXS-12 NDA for narcolepsy imminent, and Solriamfetol trials expanding to ADHD, binge eating, and MDD with hypersomnia.<br>

                                

Commercial Performance

The company's commercial performance was driven by the strong sales of Auvelity, Sunosi, and Cymbravo. Auvelity achieved over 225,000 prescriptions in the quarter, representing 42% year-over-year growth and 8% sequential growth. Ari Maizel highlighted that the company has initiated its third and largest expansion of the Auvelity sales force to approximately 600 sales representatives. Sunosi delivered another strong quarter of performance, with over 54,000 prescriptions representing 11% year-over-year and 3% sequential growth.

Pipeline Advancements

Axsome is advancing a broad and innovative CNS pipeline, including five novel product candidates across nine high-impact indications. The sNDA for Auvelity in Alzheimer's disease agitation has been accepted with priority review designation, and the company is preparing for launch. The company is also advancing its planned Phase III trial of AXS-05 in smoking cessation and expects to submit its NDA package for AXS-12 in narcolepsy imminently.

Financial Position

The company ended the year with $323 million in cash and cash equivalents, which is expected to be sufficient to fund anticipated operations into cash flow positivity. The company's financial results reflect its growing commercial portfolio and the continued advancement of its industry-leading CNS pipeline. Total cost of revenue was $12.3 million and $47.5 million for the fourth quarter and full year of 2025, respectively.

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 51.7%. The company's current valuation metrics include a P/S Ratio of 13.8 and an EV/EBITDA of -51.57. These metrics suggest that the market is pricing in significant growth expectations for the company. With a strong commercial performance and advancing pipeline, Axsome is poised to deliver innovative medicines and generate significant value through the next decade.

3. NewsRoom

Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar -10

Source: seekingalpha.com

2 Under-the-Radar Stocks to Buy and Hold

Mar -10

Source: fool.com

Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision

Mar -09

Source: fool.com

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Feb -25

Source: globenewswire.com

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Feb -24

Source: zacks.com

Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued

Feb -23

Source: seekingalpha.com

Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings

Feb -23

Source: zacks.com

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Feb -23

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.30%)

6. Segments

Novel Therapies

Expected Growth: 10.3%

Growing prevalence of CNS disorders, increasing demand for innovative treatments, and Axsome's novel therapies pipeline are expected to drive growth in the CNS disorder treatment market.

7. Detailed Products

AXS-05

A novel, oral, investigational medicine for the treatment of major depressive disorder (MDD) and other central nervous system (CNS) disorders.

AXS-07

A novel, oral, investigational medicine for the acute treatment of migraine.

AXS-12

A novel, oral, investigational medicine for the treatment of narcolepsy.

8. Axsome Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Axsome Therapeutics, Inc. operates in the pharmaceutical industry, where substitutes are available, but they are not easily interchangeable. The company's products are specialized, and patients may not easily switch to alternative treatments.

Bargaining Power Of Customers

Axsome Therapeutics, Inc. primarily sells its products to wholesalers, distributors, and pharmacies, which then sell them to patients. The company has a diverse customer base, and no single customer has significant bargaining power.

Bargaining Power Of Suppliers

Axsome Therapeutics, Inc. relies on a limited number of suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still have some leverage, particularly if they provide specialized or critical components.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. New entrants may find it challenging to enter the market and compete with established players like Axsome Therapeutics, Inc.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Axsome Therapeutics, Inc. operates in a niche market, but still faces competition from other companies developing similar products.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	48.43%
Debt Cost	4.24%
Equity Weight	51.57%
Equity Cost	10.30%
WACC	7.36%
Leverage	93.91%

11. Quality Control: Axsome Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 2.1

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

Arrowhead Pharmaceuticals

A-Score: 4.8/10

Value: 6.0

Growth: 8.6

Quality: 3.3

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

Axsome Therapeutics

A-Score: 4.8/10

Value: 6.0

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 9.5

Volatility: 5.3

1-Year Total Return ->

TG Therapeutics

A-Score: 4.2/10

Value: 2.0

Growth: 8.1

Quality: 7.7

Yield: 0.0

Momentum: 4.5

Volatility: 3.0

1-Year Total Return ->

Ultragenyx Pharmaceutical

A-Score: 3.3/10

Value: 6.4

Growth: 4.7

Quality: 3.8

Yield: 0.0

Momentum: 1.0

Volatility: 3.7

1-Year Total Return ->

Intellia Therapeutics

A-Score: 3.0/10

Value: 7.3

Growth: 2.8

Quality: 4.6

Yield: 0.0

Momentum: 2.0

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

44.83%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.36%

Axsome Therapeutics, Inc. - US05464T1043

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on AXSM

1.c. Company Highlights

Lower Growth

Average Quality

Fairly Valued

Earnings Beats

Revenues Beats

Average Yield

Revenues Miss

Stable Momentum

Medium Volatility

Strong Momentum

Less Volatile

Earnings Miss

2. Axsome Therapeutics' Q4 2025 Earnings: Strong Revenue Growth and Pipeline Advancements

Commercial Performance

Pipeline Advancements

Financial Position

Valuation and Growth Prospects

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.30%)

6. Segments

Novel Therapies

Expected Growth: 10.3%

7. Detailed Products

AXS-05

AXS-07

AXS-12

8. Axsome Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Axsome Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

159.5$

Current Price

159.5$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA